Lactoferrin levels in Cerebrospinal fluid exhibits isoform-specific associations with Alzheimer's disease

Feiyang Zhao[a,b], Raquel Puerta[c], Yaxi Wang[d], Eva Beckett[a], Pablo Gacia Gonzalez[c,e], Sergi Valero[c,e], Adelina Orellana[c], Pilar Sanz[c], Tiffany F. Kautz[a], Maria Victoria Fernandez[c], Amanda Cano[c,e], Sudha Seshadri[a,f,g], Merce Boada[c,e], Valentina R. Garbarino*[a,h], Agustin Ruiz*[a,b,c,e]

[a]Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, The University of Texas at San Antonio, San Antonio, TX, USA

[b]Department of Microbiology, Immunology and Molecular Genetics. Long School of Medicine, The University of Texas at San Antonio, San Antonio, TX, USA

[c]Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain

[d]Department of Biochemistry and Structural Biology. Long School of Medicine. University of Texas San Antonio, TX, USA

[e]CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain

[f]School of Public Health, Boston University and the National Heart, Lung, and Blood Institute Framingham Heart Study, Boston, MA, USA

[g]Department of Neurology, Boston University School of Medicine, Boston, MA, USA

[h]Department of Cell Systems & Anatomy, The University of Texas at San Antonio, San Antonio, TX, USA

*Co-corresponding authors: Agustin Ruiz MD, PhD (ruiza5@uthscsa.edu), Valentina R. Garbarino (garbarino@uthscsa.edu)

ABSTRACT

Background: Pathological changes in Alzheimer's disease (AD) begin years before the onset of clinical symptoms. Developing cost-effective and minimally invasive biomarkers for preclinical diagnosis remains a critical goal in the field. Lactoferrin, an iron-binding glycoprotein, has emerged as a promising candidate due to its multifunctional roles reported in previous studies. However, whether lactoferrin levels in biofluids are associated with established AD biomarkers, and whether it can serve as a reliable diagnostic indicator, remains controversial.

Methods: We analyzed SOMAscan proteomic data from 1,367 paired plasma and cerebrospinal fluid (CSF) samples from the ACE Alzheimer's Center Barcelona cohort to evaluate lactoferrin levels. Associations between two lactoferrin-targeting SOMAmers and classical AD biomarkers, including total tau (t-tau), phosphorylated tau (p-tau), and amyloid-beta 42 (Aβ42), were assessed. The prognostic value of lactoferrin in predicting dementia progression was further evaluated using survival analysis.

Findings: Among the two lactoferrin-targeting SOMAmers, one showed a weak and exclusive association with CSF Aβ42 and syndromic status, while the other was weakly associated with CSF p-tau and t-tau AD biomarker levels, and also exhibited a stratification pattern by LTF signal strength. Furthermore, lactoferrin levels were not significantly associated with the progression from mild cognitive impairment (MCI) to dementia.

Interpretation: Isoform-specific lactoferrin expression changes in cerebrospinal fluid (CSF), but not plasma, appears to have biological relevance and diagnostic biomarker potential for AD.

Keywords: Alzheimer's disease, Lactoferrin, CSF, Plasma, Biomarkers

Introduction

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, which is characterized by progressive cognitive decline, loss of neurons, amyloid-beta (Aβ) deposition, and tau pathology [1, 2]. Combinations of clinical assessment, structural and functional neuroimaging, and evaluation of cerebrospinal fluid (CSF) and blood plasma based pathological markers, are considered well-established AD biomarkers and show a good diagnostic precision to detect AD progression [2, 3]. Despite recent advancements in diagnostic tools, current biomarkers remain invasive or expensive, highlighting an urgent need for new diagnostic biomarkers to address these limitations. Furthermore, the underlying cause of neurodegenerative disease remains unclear. Even the widely accepted hypothesis, that Aβ aggregation leads to a pathological cascade, cannot alone fully explain the pathological initiation and progression of neurodegenerative disease [3, 4]. In the last decades, there has been growing recognition that immune system declines during aging and persistent inflammation stimulation induced by microbes or other stimuli such misfolded proteins in the brain contribute to Aβ deposition, progressive synaptic dysfunction, neuronal loss, and ultimately AD [5]. In support of this hypothesis, infections of the central nervous system are known to be associated with AD-like pathology [6-10]. Furthermore, oral and gut microorganisms are now known to play a role in the cascade of immune dysregulating events preceding AD [11, 12]. The involvement of pathogen-targeting agents and viral infection–related markers in of the brain such as amyloid aggregation, reinforces the potential association between AD and immunologic response of the central nervous system to infection(s) [12, 13]. These pieces of evidence suggest an important role of both local and systemic inflammation in AD pathogenesis.

As primary effector molecules of innate immunity, antimicrobial proteins and peptides may contribute significantly to AD development [14, 15], specifically Aβ pathology [16-19]. Lactoferrin (LTF), an iron-binding glycoprotein involved in innate immunity, acting as part of the body’s first line of defense against bacterial, viral, fungal, inflammatory and carcinogenic compounds [20], has attracted attention in recent years for its potential role

82 in neurodegeneration [21-23]. Beyond exocrine secretion by epithelial cells in most
83 mucosal tissues, it is also expressed by the cells of the innate immune system throughout
84 the body, including peripheral neutrophil leukocytes and monocytes, and microglial within
85 the brain [24, 25]. In neutrophils, LTF is stored in the secondary granules and released
86 into the blood or infected tissues at high concentrations during inflammation. LTFs
87 expression and release occur not only in peripheral tissues but also in the central nervous
88 system, where microglial cells can release LTF through degranulation, particularly under
89 inflammatory conditions [25, 26].

90 In the last decade, several studies have reported altered LTF abundance in biological
91 fluids of AD patients. For instance, through a cross-sectional investigation, Carro, et al.
92 found that salivary LTF expression can discriminate AD patients from healthy controls
93 more accurately than Aβ42 and total-tau (t-tau) in CSF [27]. The same research group
94 further revealed that salivary LTF can reliably distinguish prodromal AD and clinical AD
95 groups from frontotemporal dementia (FTD) with high accuracy [28]. Through a later study,
96 they also demonstrated negative associations between salivary LTF and Aβ load, middle
97 temporal cortex thickness, increased FDG uptake in posterior cingulate cortex, and
98 poorer memory [29]. Subsequent studies from these research groups have consistently
99 validated their previous findings, that salivary LTF may be a promising non-invasive and
100 cost-effective AD biomarker. However, a subsequent, independent follow-up study in a
101 mixed memory clinic cohort did not find an association between lactoferrin levels in
102 cerebrospinal fluid or saliva and cognitive diagnoses or pathological AD markers (t-tau,
103 p-tau, Aβ42) [30]. These conflicting findings from different research groups highlight the
104 need for standardized sample collection and assessment methods, and a potential
105 unexpectedly complex role of LTF in specific neurodegenerative disease pathology and
106 progression—complexity that may not be fully captured or detectable by current studies
107 and evaluation methods. Disagreement between these studies may stem from several
108 complex aspects of neurodegenerative disease pathology and the biology of LTF that is
109 endogenously generated by a variety of cell types including: immune cell, glial cells,
110 epithelial cells [25, 31]. LTF not only exists in the neural system but also within the
111 immune, digestive, circulatory and reproductive systems, so it important to consider that

circulating LTF levels are potentially affected by multiple tissues, environmental exposures and potentially even some genetic factors.

To explore the potential involvement of LTF in AD and strengthen the fields understanding of the role of LTF in neurodegenerative disease, we examined data from a novel and independent cohort. We utilized existing proteomic data from the ACE Alzheimer Center Barcelona (Spain), which includes a larger number of participants with paired CSF and plasma proteomic profiles measured by the high-throughput SOMAscan 7K platform. By leveraging this well-characterized dataset along with readily available detailed clinical phenotyping, we aimed to clarify the relationship between LTF and AD across CSF and plasma, and to assess whether LTF holds promise as a disease-associated or stage-specific biomarker. This study provides an opportunity to re-evaluate the role of LTF in AD pathogenesis with improved statistical robustness and biological resolution.

2. Material and methods

2.1. Study Cohort

We used the ACE cohort for all analysis in this study. In brief, a cohort of well characterized CSF samples established through the ACE Memory Clinic in Barcelona. Participants who presented for cognitive evaluation and met criteria for lumbar puncture were recruited. On the same day, biological samples were collected, along with clinical, cognitive, and imaging data. Follow-up assessments were conducted annually. The cohort consisted of individuals with MCI, dementia, or subjective cognitive concerns. Diagnoses were made by a multidisciplinary team based on a comprehensive neuropsychological evaluation. Progression to dementia was monitored over time to classify participants as either converters or stable. Converters are defined as subjects who converted to dementia, including AD, vascular dementia, mixed dementia (AD with cerebrovascular disease), frontotemporal dementia, or dementia with Lewy bodies over the study period (from the baseline assessment to last available visit; max = 7.57 years, mean = 2.81 years), and were classified as MCI converters according to previous definitions [32]. All of converter subjects had a Clinical Dementia Rating (CDR) score. In

141 contrast, those subjects who remained stable at follow-ups were classified as stable or
142 non-MCI converters. Sample processing followed standardized procedures [33]. Briefly,
143 CSF and plasma were centrifuged and stored at −80 °C. Core CSF biomarkers (Aβ40,
144 Aβ42, t-tau, and p-tau181) were quantified using validated immunoassay platforms, with
145 predefined thresholds used for AT(N) classification according to the 2018 NIA-AA
146 Research Framework [34]. For details on sample acquisition and collection of additional
147 information, refer to previous publications [35-38].

148 2.2 Protein analysis in CSF and plasma using the SOMAscan panel

149 Paired CSF and plasma proteomic data from 1,369 ACE cohort participants were
150 generated using the SOMAscan 7K Assay Kit in the context of the HARPONE project and
151 the Global Neurodegeneration Proteomics Consortium [36-38]. Briefly, this platform
152 measures approximately 7,000 proteins per sample. In brief, this assay uses 50 μL of
153 either CSF or plasma and employs modified DNA aptamers (SOMAmers) to quantify
154 specific protein levels. Initially, proteins captured by immobilized aptamers, facilitated by
155 streptavidin beads, and tagged with fluorescent markers. After removal of unbound
156 proteins, the streptavidin beads released using ultraviolet light. The protein-aptamer
157 complexes were re-captured by monomeric avidin. The detail of the assay is described
158 elsewhere [39]. Protein abundances were normalized using the adaptive normalization
159 by maximum likelihood (ANML) approach, following previously described procedures [39].
160 The data were reported in normalized relative fluorescence units (RFU). For the LTF gene
161 (UniProt ID: P02788), two SOMAmers - Seq.14755.4 and Seq.2780.35 - were designed
162 on the SOMAscan platform based on the target coding information provided by
163 SomaLogic. These two SOMAmers have different dilution factors: 20% for Seq.14755.4
164 and 0.005% for Seq.2780.35 (Table S1). For clarity, we henceforth refer to Seq.14755.4
165 as LTF1 and Seq.2780.35 as LTF2 throughout this manuscript.

2.2. Statistical methods

a. Identification of the association between LTF expression and dementia diagnosis

Prior to statistical analysis, SOMAmer measurements were log-transformed and standardized using z-score normalization because the long tail of the SOMAmer signal among participants. The normality of LTF1/2 distribution was evaluated with Shapiro.test function in R. To examine the association between LTF levels and AD-related biomarkers, the Spearman test was applied to compare the distributions of LTF SOMAmers, given their non-normal distribution. For LTF1, participants were further categorized into high (LTF1-high) and low (LTF1-low) groups to evaluate group-wise differences. Spearman correlation analysis was used to assess the relationships between LTF levels (in CSF and plasma), AD biomarkers expression, and AD risk loci identified in a previous genome-wide association study [40]. To address potential inaccuracies in p-values arising from tied ranks in Spearman correlation tests, genotype dosages were transformed into categorical values (0, 1, or 2), followed by Fisher's exact test using the fisher.test function with simulate.p.value = TRUE and B = 10,000. All statistical analyses were performed using R (v4.3).

b. Assessment of associations between clinical traits and LTF protein expression

Patients were categorized into case and control groups based on AT(N) biomarker classification (status). Individuals with an A-T-(N)- profile were assigned to the control group, while those with A+ (regardless of T or N status) were classified as cases. For further comparison, we also compared A+ v.s. A-, A+T+ v.s. A-T-, A+T+ v.s. A-T- (include A-T-(N)-). Participants were classified into three diagnostic categories: cognitively normal controls (including Subjective Cognitive Decline (SCD)), mild cognitive impairment (MCI), and dementia. Due to the non-linear relation between LTF and the biomarkers, we categorize the samples into high and low according to the signals of LTF1 (High, P: > mean + sd; Low, N: < mean + standard deviation) for correlation analysis. For LTF2, the outliers were Winsorized (mean ± 3 standard deviation).

c. Identification of the LTF central nervous system and systemic co-regulatory gene networks

To compare the LTF-associated genes with known co-regulated expression profiles, gene clusters containing 237 brain-expressed genes and 154 bone marrow–expressed genes were retrieved from the Human Protein Atlas database [41]. LTF-associated proteins were identified using Spearman correlation analysis via the cor.test function in R. Genes with an absolute Spearman correlation coefficient greater than 0.1 and ranked among the top 250 proteins by correlation were selected for the positively (+) and negatively (-) correlated groups, respectively. Multiple testing correction was applied using the false discovery rate (FDR) method. Fisher's exact test was used to assess enrichment by comparing the identified genes from the proteomic data with gene sets from the Human Protein Atlas database.

d. Cox proportional hazards models

We applied a series of Cox proportional hazards regression models to assess the association between LTF1/LTF2 and the risk of conversion to dementia. Three hierarchical models were constructed to evaluate the robustness of the associations under different levels of covariate adjustment: Model 1 (unadjusted model): LTF1 or LTF2 signal (LTF) was entered independently to estimate its association with AD conversion. Model 2 (demographic-adjusted model): Each variable was included in a Cox model adjusted for age at lumbar puncture (Age_LP), sex, years of education (Education), and baseline Mini-Mental State Examination (MMSE) score. Model 3 (Fully adjusted model): In addition to the covariates in Model 2, we further adjusted for polygenic risk score (PRS), CSF phosphorylated tau (p-tau) levels, and APOE genotype. Statistical tests were performed between the LTF1-high and -low groups. For LTF2, statistical significance was assessed by comparing samples with abundance above versus below the median. Hazard ratios (HRs), 95% confidence intervals (CIs), and p-values were reported for each model. Survival time was defined as the interval from MCI to dementia conversion or last follow-up assessment.

2.3. Funding source

The study was partially funded by, the Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 (Belgium) and Janssen Pharmaceutica (Beerse, Belgium). VRG was/is supported by 5T-P30-AG066546-03, P30-AG013319, and TR004529. Additionally, AR is also supported by the STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Health. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer's and Neurodegenerative Diseases and The Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer's and Neurodegenerative Diseases.

The funders had no role in the conceptualization, study design, data collection, analysis, interpretation of data, in writing the paper or in the decision to submit the paper for publication.

3. Results

3.1 LTF abundance in CSF and Plasma

To investigate whether LTF changes contribute to AD progression and the possibility to serve as a potential biofluid biomarker for AD, we accessed the plasma and CSF profiles of 1,369 individuals from the ACE CSF cohort. In this cohort, two samples lacked detectable signals for both LTF-targeting SOMAmers. Analysis included a total of 792 females and 577 males. The subjects consisted of 113 (8.27%) healthy controls; 833 (60.9%) diagnosed with MCI at baseline–of whom 44.1% converted to dementia during the follow-up visit, with CSF samples collected while they are still in MCI stage–and 394 (28.2%) subjects diagnosed with dementia at the time of the lumbar puncture (Table S2). The mean age at the time of lumbar puncture was 72.7 ± 8.8 years. As expected, the frequency of the *APOE* ε4 allele was higher in the dementia group (21.9%) compared to MCI group (19.9%) and control group (13.1%). Detailed demographic and clinical characteristics are summarized in Table S2. We first investigated the distribution of all SOMAmers and noticed that distribution patterns of most SOMAmer did not follow a

250 normal distribution including LTF1/2 in both CSF and Plasma (**Fig. 1A**). For each
251 individual, two SOMAmers that target LTF were measured in both CSF and plasma. For
252 LTF1 (seq.14755.4) most individuals exhibited low expression in both CSF (132 $\pm$ 79)
253 and plasma (370 $\pm$ 469) , while a small subset showed high expression in either fluid (**Fig.**
254 **1A, B**). The other SOMAmer (LTF2; seq.2780.35) displayed high expression in plasma
255 (1,260 $\pm$ 4,703) for a small group of individuals (**Fig. 1A, C)** and another group of samples
256 showed CSF-specifically high expression (CSF: 19,951 $\pm$ 20,804). This result indicates
257 that LTF1 and LTF2 possibly represent two different isoforms or different
258 conformational/binding status of LTF. To further confirm this hypothesis, we compared
259 LTF expression between the two SOMAmers. The correlation analysis reveals the signal
260 between the two SOMAmer shows weak significant correlation only in plasma ($r = 0.22$;
261 $p < 0.001$), while there was almost no significant correlation in CSF ($r = 0.01$; $p > 0.05$;
262 **Fig 1D**). Meanwhile, results revealed no significant correlation between CSF and plasma
263 ($r = 0.02$; $p > 0.05$) for LTF2, with a similarly negligible negative correlation for LTF1 ($r =$
264 -0.09; $p < 0.01$; **Fig 1D**). To examine whether the distribution of LTF1 in CSF is associated
265 with blood-brain barrier integrity, we performed Spearman correlation analysis between
266 LTF1, LTF2 and the albumin quotient (Qalb; a measure of blood–brain barrier (BBB)
267 leakage), revealing that only CSF LTF1 levels ($r = 0.1$; $p < 0.001$; **Fig. 1E**), not LTF2 ($r =$
268 -0.01; $p > 0.05$), weakly associated with Qalb.

269

270 3.2 LTF Levels and AD Biomarkers

271 We sought to determine whether LTF expression is associated with established CSF
272 AT(N) biomarkers in the ACE CSF cohort. To address this, we performed Spearman
273 correlation analysis between LTF1 and LTF2 signals with Aβ, p-tau and t-tau (**Fig 1E**). We
274 found that LTF1 in CSF showed a weak positive correlation with total-tau ($r = 0.16$; $p <$
275 0.001), p-tau ($r = 0.16$; $p < 0.001$) and a negligible correlation with Aβ ($r = 0.07$; $p < 0.05$).
276 In contrast, LTF2 showed a weak negative correlation with Aβ ($r = -0.10$; $p < 0.001$) and
277 no significant association with p-tau ($r = 0.01$; $p > 0.05$) or t-tau ($r = 0.01$; $p > 0.05$). Based
278 on the distribution patterns of LTF1 and LTF2 in CSF and plasma (**Fig. 1A**), we

279 hypothesized that the weak correlation might reflect the heterogeneity in expression
280 across subgroups of participants. LTF1 displayed a non-normal distribution, suggesting it
281 may be expressed in only a subset of individuals. LTF2 appears to follow a normal
282 distribution, with a few distinct outliers. To test this hypothesis, we stratified the samples
283 based on LTF1 signal intensity: high (≥ mean + SD) and low (< mean + SD) and remove
284 the outliers for LTF2. We then repeated the correlation analysis. For LTF2, results
285 remained unchanged (**Fig 1F**; **Fig S1**). In the LTF1-low group, the associations with AD
286 biomarkers were stable (**Fig 1G**; **Fig S1**), however, for LTF1-high groups, the direction of
287 the associations reversed, and correlation coefficient increased, particularly for Aβ (r = -
288 0.175), and p-tau (r = -0.21, **Fig 1F**; **Fig S1**). Notably, these coefficients were slightly
289 stronger than those observed between AD polygenic risk score and AD biomarkers
290 (variance explained increase by ~2.0% for p-tau, 0.2% for t-tau, and 2.2% for Aβ).

291 We then compared the LTF1 and LTF2 signal levels across participants with different
292 pathological features. The results showed that LTF2 levels in CSF were significantly
293 associated with cognitive diagnosis status (**Fig S2**), while LTF1 levels were not. To
294 determine the biological relevance of these SOMAmers signals, we performed pathway
295 enrichment analysis on the top co-regulated proteins for LTF1 and LTF2. For LTF1 (in
296 both plasma and CSF), enriched terms could not be found before stratification, however,
297 in the LTF1-high group, we observed enrichment for neural-related pathways in the
298 plasma analysis, including “neurogenesis”, “generation of neurons”, “neuron projection
299 development”, and “neuron differentiation” (**Fig 2A**). Proteins correlated with LTF1 in CSF
300 were enriched in immune-related categories such as “blood microparticle” and
301 “complement and coagulation cascades” (**Fig 2C**). To further explore the differences of
302 high and low populations, we analyzed the LTF-associated protein networks using
303 SomaScan data. Correlation analyses between LTF1/LTF2 and all other quantified
304 proteins were performed, and significantly coregulated proteins were compared with LTF
305 interactors identified in single-cell RNA-seq data from brain and bone marrow. Before
306 stratification, no enrichment overlap was found for LTF1 in CSF or plasma. However, in
307 the positive group, significant overlap was observed with bone marrow–derived co-
308 regulated genes (**Fig 3**).

LTF2 showed modest enrichment for terms like “secretory granule lumen” and “vesicle lumen” (**Fig. 2B**). Overlap with bone marrow-derived networks was also confirmed. Together, these findings suggest that LTF1 and LTF2 are associated with distinct proteomic profiles and biological processes, possibly reflecting different aspects of the LTF locus biology and AD pathology. Importantly, the diagnostic relevance of LTF1 appears to be limited to specific subgroups of samples that have higher expression LTF1 signal.

3.3 CSF and Plasma LTF Levels Are Not Associated with AD Progression or Genetic Risk

We next examined whether LTF expression is associated with the progression from mild cognitive impairment (MCI) to dementia. Using Cox regression models, we found that neither LTF1 nor LTF2 expression in cerebrospinal fluid (CSF) or plasma was significantly associated with disease progression. To account for potential confounding variables, we implemented nested Cox regression models. The second model included adjustments for age, sex, years of education, and MMSE score, while the third model further adjusted for polygenic risk score (PRS), p-tau levels, and APOE genotype. Across all models, LTF1 and LTF2 levels in both CSF and plasma were not significantly correlated with conversion from MCI to dementia (**Fig. 4**).

Additionally, we assessed whether variation in LTF expression could be driven by genetic risk for AD. However, no significant associations were found between AD-associated genetic variants and LTF expression levels in either CSF or plasma. These findings suggest that, despite LTF’s known roles in immune response and neuroinflammation, its expression levels in CSF and plasma do not appear to reflect AD progression or genetic susceptibility. This may indicate that LTF biomarker potential may be limited to identifying the presence of disease pathology, rather than providing a biomarker read for disease risk phenoconversion or genetic risk stratification in AD, at least in the context of plasma and CSF expression.

4. Discussion

Salivary LTF levels remain a controversial candidate biomarker for AD. To further investigate the potential role of LTF as a biomarker for AD, we examined LTF expression in both systemic and central compartments in the context of the AD diagnostic continuum in the largest dataset reported to date (N= 1,367). Our rationale was that if salivary LTF levels are directly associated with AD, similar associations might be detectable in other biological fluids – particularly in CSF, which is in closer contact with the neuropathological changes characteristic of the disease.

Our study was inspired by previous work suggesting a potential link between LTF and AD. Specifically, a 2017 study conducted a cross-sectional analysis using saliva samples and proposed salivary LTF as a promising biomarker to differentiate mild cognitive impairment (MCI) and AD from healthy controls [27]. Two subsequent studies by the same group further supported this finding: one demonstrating that salivary LFT could distinguish AD from other forms of dementia [28], and the other showed that LTF abundance is closely related to AD pathology [29]. Additional support came from a pilot study that reported significant associations between salivary LTF levels and cognitive performance, as measured by the Digit Span Memory Test and Mental Rotation Test scores [42]. Collectively, these studies suggest that reduced lactoferrin levels in saliva may serve as a non-invasive biomarker for AD diagnosis. However, a study from an independent laboratory failed to replicate these findings in a consecutive, mixed memory clinic cohort [30], casting doubt on the reliability of salivary LTF as an AD biomarker. Each of these investigations were based on relatively small cohorts (N = 17-274)[27-30, 42], which may reduce statistical power and contribute to inconsistent findings [43]. Thus, it remains to be determined whether changes in LTF levels are part of the causal chain driving neurodegeneration, or merely epiphenomena reflecting systemic or local inflammation. Additionally, the function of LTF is complex – it can exhibit both pro-inflammatory and anti-inflammatory properties depending on the context of response [31]. Despite growing

interest in LTF as a potential biomarker or mediator in AD, several limitations complicate its study across different biological compartments. Beyond its role in inflammation, LTF can act as a mediator of both innate and adaptive responses by promoting the maturation, differentiation and activation of T- B-lymphocytes [44]. Its molecular complexity further challenges interpretation: LTF exists in multiple isoforms α, β, γ, and δ-LTF. The canonical isoform is primarily expressed in neutrophils and epithelial cell, secreted into exocrine inflamed tissue and fluid, while δ-LTF localizes to cytoplasm and act as a transcription factor [45, 46]. Additionally, Importantly, iron-binding status further complicates LTF biology. LTF exists in different iron-binding states including the iron-free (apo-LTF), native and iron-saturated forms (holo-LTF), which may have distinct biological functions and activities [47, 48]. It circulates in apo (iron-free), mono-ferric, and holo (iron-saturated) forms, each associated with different functions [47, 48]. Apo-LTF mainly sequesters iron, while holo-LTF can activate immune signaling pathways via receptors such as LRP1 and CXCR4, influencing MAPK, AKT, and NF-κB pathways [49, 50]. Proteolytic cleavage of LTF can also generate antimicrobial peptides known as lactoferricins, which exhibit different functional properties compared to native LTF [51]. Despite this molecular complexity, most current studies-including those evaluating its potential as an AD biomarker - use ELISA kits based on a single LTF antibody, which typically quantifies total or a single protein isoform, without distinguishing among various functional forms. Moreover, these studies often rely on correlation analyses between LTF levels and disease biomarkers, without addressing the biological significance or mechanistic relevance of inter-individual variation in LTF expression.

In our study, we aimed to explore the relationship between LTF levels in CSF and plasma with AD status, disease progression and AT(N) biomarkers. Unlike previous work focusing on salivary LTF, we used data derived from high-throughput SOMAscan proteomics on larger, well-characterized cognitive and biomarker cohorts. Our findings suggest that the relationship between LTF abundance and AD biomarkers is complex and compartment specific.

391 **1. Lactoferrin Expression in CSF and Plasma: A Complex and Inconsistent**
392 **Association with AD Biomarkers**

393 Three key observations highlight the complexity of interpreting LTF measurements
394 using SOMAmer technology: 1. Lack of consistency between SOMAmers: The two
395 SOMAmers targeting to LTF (LTF1 and LTF2) showed markedly different distributions and
396 negligible correlation in both CSF and plasma (**Fig 1D**). 2. Weak systemic-central
397 correlation: Correlation between LTF SOMAmer signals between CSF and plasma was
398 weak (**Fig 1E**). 3. Inconsistent association with AD biomarkers: In CSF, LTF1 displayed
399 weak and even opposing correlations with AD biomarkers (Aβ, p-tau, t-tau) depending on
400 LTF-high vs. low subgroups (**Fig 1F**, **G**). Meanwhile, LTF1 is correlated with Qalb, but not
401 for LTF2, suggesting that LTF1 may be more sensitive to barrier/inflammation-related
402 signals, whereas LTF2 likely captures a different conformational or compartment-specific
403 facet of LTF. Notably, CSF LTF2 levels were significantly higher in A+ than A-T-N-
404 individuals (**Fig.S2**, $p = 0.0019$), and this difference was replicated in comparisons
405 between A+T+ and A-T- groups ($p = 0.0068$). This pattern was not observed for LTF1.
406 Together, these findings indicate that LTF measurements obtained with SOMAmer
407 reagents are heterogeneous across targets and fluids.

408 **2. Comparison with Previous Salivary Lactoferrin Studies**

409 The most prominent studies evaluating LTF as an AD biomarker were conducted
410 using saliva samples. Carro, et al. [27] first reported positive associations between
411 salivary LTF and CSF Aβ42, and negative association with t-tau, suggesting that lower
412 levels of salivary LTF are associated with increased markers of AD pathology. Later
413 studies from the same group supported the discriminatory power of salivary LTF between
414 AD and other dementia types [28], and also linked it to cortical Aβ load and brain integrity
415 in aging adults [29]. A separate pilot study [42] found lower salivary LTF in participants
416 with much more severe cognitive impairment.

417 In contrast, our data from CSF and plasma cohorts challenge these findings. We
418 found there is higher CSF LTF2 levels in MCI dementia compared with control (Kruskal-
419 Wallis test; $p = 0.05$). These findings were consistent with those of another independent

study [30], which analyzed 222 matched saliva and CSF samples from a consecutive, mixed memory clinic population and found both CSF and saliva LTF expression have higher LTF expression in MCI and AD participants than healthy control although the difference is not statically significant. This discrepancy may arise from difference in sample origin, population heterogeneity, or the biological nature of LTF secretion in different compartments. It is possible that LTF expression in CSF do not reflect the association previously described for salivary LTF in AD. If the salivary LTF finding is genuine, it is most likely capturing a biological signal that is not adequately measured by SOMAscan assays in CSF or plasma. Moreover, the lack of saliva samples in our study limits direct comparability.

3. Molecular and Functional Complexity of Lactoferrin

The multifunctionality of LTF likely contributes to these inconsistent results. LTF is involved in both innate and adaptive immune responses, influencing T- and B-cell activation [44]. It exists in multiple isoforms (α, β, γ, δ), with distinct localization and functions. For example, δ-lactoferrin acts as a transcription factor and is localized in the cytoplasm [46]. Meanwhile, iron-binding status of LTF also potentially impact on it biological functions and activities [47, 48]. Another aspect is the technical considerations in SOMAmer-Based measurement. According to SomaLogic documentation, LTF1 targets amino acids 20 – 710, while LTF2 spans the full LTF sequence. These reagents may bind distinct epitopes, requiring different dilutions and potentially detecting different isoforms or modifications of LTF. Consistent with this notion, LTF1 and LTF2 show distinct associations with Qalb, suggesting that structural and conformational differences may underlie compartment-specific behavior and, consequently, their differential relationships with disease biomarkers. This distinction may partly explain the divergent results we observed.

4. Limitations and Future Directions

Our study benefits from two notable key methodological strengths, multi-tissue protein profiling, enabling cross-compartment comparison; and large-scale proteomic-level analysis, providing consistently measured insights into disease relevant proteins.

However, several limitations must be acknowledged. First, our sample size, especially for healthy controls, may limit our statistical power. Secondly, though we had access to CSF and plasma proteomics, we lack this data in a cohort of saliva samples, which restricts our corss-compartment analysis and limits our interpretation of the data compared to previously published reports. We also acknowledge potential confounding introduced by unmeasured variables such as oral health, diet, or use of specific medications that may influence LTF levels or tissue secretion. Unfortunately, no isoform-level validation of SOMAmers exists to provide additional insight into the protein, protein-isoform, or component that is being measured, a critical consideration for proteins with known physical and functional diversity. Finally, we acknowledge that we have pulled our samples from a heterogeneous memory clinic population, which likely dilutes group-level effects that might otherwise be detectable.

Future work should include experimental validation of LTF isoforms and iron-binding forms across compartments, as well as mechanistic studies to clarify their roles in neuroinflammation and AD pathology.

5. Clinical Implications and Conclusions

Although lactoferrin shows some association with AD-related markers (particularly Aβ), its value as a biomarker remains uncertain due to its molecular complexity, compartment-specific behavior, and methodological limitations. Integrative multi-omics studies [36] emphasize the disconnection between protein abundance and genetic risk, reinforcing the need to explore regulatory and post-translational mechanisms. While exogenous LTF has shown therapeutic effects in preclinical models [52], such interventions may only benefit individuals with active LTF-related pathways. Identifying LTF-high subgroups in CSF or plasma could help stratify patients and tailor future treatments. However, it requires improved testing systems that could differentiate between LTF isoforms, their fragments, and their iron-binding states for disentangling the systemic and brain-specific roles of LTF in the pathophysiology of AD and related dementias. Ultimately, a deeper understanding of LTF's systemic and brain-specific roles is crucial for developing effective, personalized strategies for AD diagnosis and therapy.

Contributors

Conceptualization, Agustin Ruiz, Valentina R. Garbarino; Formal analysis, Feiyang Zhao; Funding acquisition, Agustin Ruiz, Sudha Seshadri, Merce Boada, Sergi Valero, Amanda Cano and Maria Victoria Fernandez; Methodology, Feiyang Zhao, Agustin Ruiz; Project administration, Feiyang Zhao, Agustin Ruiz; Supervision, Merce Boada, Agustin Ruiz, Sudha Seshadri; Validation, Feiyang Zhao; Visualization, Feiyang Zhao; Writing – original draft, Feiyang Zhao, Agustin Ruiz, Yaxi Wang; Writing – review & editing, Valentina R. Garbarino, Tiffany Kautz, Agustin Ruiz, Sudha Seshadri, Yaxi Wang, Eva Beckett, Feiyang Zhao; Raquel Puerta, Pablo Gacia Gonzalez, Maria Victoria Fernandez and Amanda Cano performed proteome database generation and curation, APOE genotyping GWAS analysis and PRS construction; Clinical and molecular data acquisition, Merce Boada, Amanda Cano, Adelina Orellana, Pilar Sanz and Maria Victoria Fernandez. All authors had access to the data and accept the responsibility to submit for publication. All authors have read and approved the final version of the manuscript.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgments

We would like to thank the patients and controls who participated in this project. We are also grateful to the ACE Alzheimer Center Barcelona Memory Clinic, the clinical trial and nurse station staff involved in participant evaluations and case management, for their passionate dedication to the patients and families contributing to this research.

References

[1] Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol. 2004;6(11):1054-61.

[2] Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017;13(3):274-84.

[3] Grande G, Valletta M, Rizzuto D, Xia X, Qiu C, Orsini N, et al. Blood-based biomarkers of Alzheimer's disease and incident dementia in the community. Nat Med. 2025;31(6):2027-35.

[4] Drachman DA. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement. 2014;10(3):372-80.

[5] Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, et al. Microbes and Alzheimer's Disease. J Alzheimers Dis. 2016;51(4):979-84.

[6] Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, et al. Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol. 1994;53(3):231-8.

[7] Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS. 2005;19(4):407-11.

[8] Smith DB, Simmonds P, Bell JE. Brain viral burden, neuroinflammation and neurodegeneration in HAART-treated HIV positive injecting drug users. J Neurovirol. 2014;20(1):28-38.

[9] McQuaid S, Allen IV, McMahon J, Kirk J. Association of measles virus with neurofibrillary tangles in subacute sclerosing panencephalitis: a combined in situ hybridization and immunocytochemical investigation. Neuropathol Appl Neurobiol. 1994;20(2):103-10.

[10] Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky KJ, et al. Alzheimer's Disease-Associated beta-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron. 2018;99(1):56-63 e3.

[11] Miklossy J. Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation. 2011;8:90.

[12] Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ. Pathogenic microbes, the microbiome, and Alzheimer's disease (AD). Front Aging Neurosci. 2014;6:127.

[13] Welling MM, Nabuurs RJ, van der Weerd L. Potential role of antimicrobial peptides in the early onset of Alzheimer's disease. Alzheimers Dement. 2015;11(1):51-7.

[14] Haage V, De Jager PL. Neuroimmune contributions to Alzheimer's disease: a focus on human data. Mol Psychiatry. 2022;27(8):3164-81.

[15] Chen L, Shen Q, Liu Y, Zhang Y, Sun L, Ma X, et al. Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases. Signal Transduct Target Ther. 2025;10(1):31.

[16] Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One. 2010;5(3):e9505.

[17] White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, et al. Alzheimer's associated beta-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS One. 2014;9(7):e101364.

[18] Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, et al. beta-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1. Biogerontology. 2015;16(1):85-98.

[19] Bourgade K, Le Page A, Bocti C, Witkowski JM, Dupuis G, Frost EH, et al. Protective Effect of Amyloid-beta Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. J Alzheimers Dis. 2016;50(4):1227-41.

[20] Wang B, Timilsena YP, Blanch E, Adhikari B. Lactoferrin: Structure, function, denaturation and digestion. Crit Rev Food Sci Nutr. 2019;59(4):580-96.

[21] Yong SJ, Veerakumarasivam A, Lim WL, Chew J. Neuroprotective Effects of Lactoferrin in Alzheimer's and Parkinson's Diseases: A Narrative Review. ACS Chem Neurosci. 2023.

[22] Qian ZM, Li W, Guo Q. Lactoferrin/lactoferrin receptor: Neurodegenerative or neuroprotective in Parkinson's disease? Ageing Res Rev. 2024;101:102474.

[23] Tsatsanis A, McCorkindale AN, Wong BX, Patrick E, Ryan TM, Evans RW, et al. The acute phase protein lactoferrin is a key feature of Alzheimer's disease and predictor of Abeta burden through induction of APP amyloidogenic processing. Mol Psychiatry. 2021;26(10):5516-31.

[24] Bennett RM, Kokocinski T. Lactoferrin content of peripheral blood cells. Br J Haematol. 1978;39(4):509-21.

[25] Fillebeen C, Ruchoux MM, Mitchell V, Vincent S, Benaissa M, Pierce A. Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res. 2001;96(1-2):103-13.

[26] Wang W, An Q, Zou Y, Dai Y, Meng Q, Zhang Y. Lactoferrin alleviates the adverse effects of early-life inflammation on depression in adults by regulating the activation of microglia. Mol Med. 2025;31(1):50.

[27] Carro E, Bartolome F, Bermejo-Pareja F, Villarejo-Galende A, Molina JA, Ortiz P, et al. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimers Dement (Amst). 2017;8:131-8.

[28] Gonzalez-Sanchez M, Bartolome F, Antequera D, Puertas-Martin V, Gonzalez P, Gomez-Grande A, et al. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine. 2020;57:102834.

[29] Reseco L, Atienza M, Fernandez-Alvarez M, Carro E, Cantero JL. Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimers Res Ther. 2021;13(1):150.

[30] Gleerup HS, Jensen CS, Hogh P, Hasselbalch SG, Simonsen AH. Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population. EBioMedicine. 2021;67:103361.

[31] Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol. 2012;90(3):252-68.

[32] Espinosa A, Alegret M, Valero S, Vinyes-Junque G, Hernandez I, Mauleon A, et al. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis. 2013;34(3):769-80.

[33] Hansson O, Batrla R, Brix B, Carrillo MC, Corradini V, Edelmayer RM, et al. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau. Alzheimers Dement. 2021;17(9):1575-82.

[34] Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62.

[35] Morato X, Puerta R, Cano A, Orellana A, de Rojas I, Capdevila M, et al. Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia. Brain Behav Immun Health. 2024;42:100899.

[36] Puerta R, de Rojas I, Garcia-Gonzalez P, Olive C, Sotolongo-Grau O, Garcia-Sanchez A, et al. Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO. Funct Integr Genomics. 2025;25(1):73.

[37] Puerta R, Cano A, Garcia-Gonzalez P, Garcia-Gutierrez F, Capdevila M, de Rojas I, et al. Head-to-Head Comparison of Aptamer- and Antibody-Based Proteomic Platforms in Human Cerebrospinal Fluid Samples from a Real-World Memory Clinic Cohort. Int J Mol Sci. 2024;26(1).

[38] Imam F, Saloner R, Vogel JW, Krish V, Abdel-Azim G, Ali M, et al. The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nat Med. 2025.

[39] Candia J, Cheung F, Kotliarov Y, Fantoni G, Sellers B, Griesman T, et al. Assessment of Variability in the SOMAscan Assay. Sci Rep. 2017;7(1):14248.

[40] Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022;54(4):412-36.

[41] Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28(12):1248-50.

[42] Hammerschlag BL, Butts B, Likos K, Verble DD, Nimmagadda N, Virani R, et al. Pilot: Salivary Lactoferrin as a Biomarker of Alzheimer's Disease. medRxiv. 2024.

[43] Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14(5):365-76.

[44] Legrand D. Overview of Lactoferrin as a Natural Immune Modulator. J Pediatr. 2016;173 Suppl:S10-5.

[45] Siebert PD, Huang BC. Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci U S A. 1997;94(6):2198-203.

[46] Mariller C, Hardiville S, Hoedt E, Huvent I, Pina-Canseco S, Pierce A. Delta-lactoferrin, an intracellular lactoferrin isoform that acts as a transcription factor. Biochem Cell Biol. 2012;90(3):307-19.

[47] Jiang R, Lopez V, Kelleher SL, Lonnerdal B. Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol. 2011;226(11):3022-31.

[48] Lopez V, Kelleher SL, Lonnerdal B. Lactoferrin receptor mediates apo- but not holo-lactoferrin internalization via clathrin-mediated endocytosis in trophoblasts. Biochem J. 2008;411(2):271-8.

[49] Tian M, Han YB, Yang GY, Li JL, Shi CS, Tian D. The role of lactoferrin in bone remodeling: evaluation of its potential in targeted delivery and treatment of metabolic bone diseases and orthopedic conditions. Front Endocrinol (Lausanne). 2023;14:1218148.

[50] Takayama Y, Aoki R, Uchida R, Tajima A, Aoki-Yoshida A. Role of CXC chemokine receptor type 4 as a lactoferrin receptor. Biochem Cell Biol. 2017;95(1):57-63.

[51] Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci. 2005;62(22):2588-98.

[52] Zheng J, Xie Y, Li F, Zhou Y, Qi L, Liu L, et al. Lactoferrin improves cognitive function and attenuates brain senescence in aged mice. Journal of Functional Foods. 2020;65:103736.



645

646

647

648

649

Fig. 1. Distributions of SOMAmer signals targeting lactoferrin (LTF) and their associations with Alzheimer's disease (AD) biomarkers.

A: Distributions of two SOMAmers targeting LTF (LTF1 on the left, LTF2 on the right) in plasma (top) and CSF (bottom). Red dotted lines indicate the cutoffs defined as mean + standard deviations for LTF1 and mean ± 3 standard deviations for LTF2. All p-value were calculated by Shapiro.test for normality test.

B–C: Comparisons of LTF1 and LTF2 signals between CSF and plasma; dotted lines represent the cutoffs shown in panel A.

D: Heatmap showing the Spearman correlation between LTF1 and LTF2.

E–G: Heatmaps showing Spearman correlations between the two SOMAmers, polygenic risk scores (PRS), and AD biomarkers. Panel E shows results for all samples; panels F and G show correlations after stratifying by LTF1 level into high and low for LTF1, respectively.



Fig. 2. GO enrichment analysis of lactoferrin-associated proteins identified from SOMAscan plasma and CSF proteomic data.

A: Significantly enriched Gene Ontology (GO) biological process terms among proteins positively correlated with the plasma-derived LTF1 signal in individuals classified as + (n = 226).

B: GO cellular component terms enriched among proteins positively correlated with the plasma-derived LTF2 signal (n = 226).

C: GO biological process and cellular component terms enriched among proteins negatively correlated with the CSF-derived LTF1 signal in the LTF1-positive group (n = 236). Enrichment significance is represented by -log10(FDR)-adjusted p-values.


Brain
P = 0.158
LTF1-high(+)
46
4
224
Bone marrow
P = 0.830
LTF1-high(+)
40
1
227
Brain
P = 0.172
LTF1-Low(+)
46
4
224
Bone marrow
P = 0.101
LTF1-Low(+)
37
4
232
Brain
P = 0.655
LTF1-high(-)
48
2
237
Bone marrow
P= 0.0328
LTF1-high(-)
36
5
234
Brain
P = 1
LTF1-low(-)
48
2
237
Bone marrow
P = 1
LTF1-low(-)
41
0
2
Brain
P = 0.17
LTF2(+)
46
4
231
Bone marrow
P = 3.7e−12
LTF2(+)
25
16
219
Brain
P = 1
LTF2(-)
50
0
1
Bone marrow
P = 1
LTF2(-)
41
0
1

674

675 **Fig. 3. Overlap between LTF-derived correlation signatures in plasma and tissue-**
676 **specific co-expression modules.**
677 Columns show tissue modules from the Human Protein Atlas database (Brain, #237 and
678 Bone marrow, #154 blue circles). Rows stratify our signatures by (i) LTF1 expression
679 stratum—LTF1-high vs LTF1-low and (ii) correlation sign with the LTF signal: "+" = top
680 positively correlated genes, "−" = top negatively correlated genes. For LTF2,
681 correlations were computed across all samples (no expression stratification). In each
682 panel, the right circle is the LTF-derived signature (yellow) and the left circle is the tissue
683 co-expression set (blue). Statistical significance was assessed with Fisher's exact test
684 (background = all tested genes after QC, n = 5,419).

685


Plasma
LTF expression
High
Low
CSF
Model2 for LTF1
HR = 0.91 (0.63−1.3)
p = 0.634
Model2 for LTF1
HR = 1.1 (0.65−1.8)
p = 0.732
Model3 for LTF1
HR_H = 0.93 (0.64−1.4)
p_H = 0.707
Model3 for LTF1
HR = 1.1 (0.69−1.9)
p = 0.595
Model2 for LTF2
HR = 0.94 (0.75−1.2)
p = 0.55
Model2 for LTF2
HR = 0.93 (0.75−1.2)
p = 0.513
Model3 for LTF2
HR = 0.88 (0.71−1.1)
p = 0.24
Model3 for LTF2
HR = 1 (0.81−1.2)
p = 0.996
Survival rate
Time (years)

Fig. 4. Survival analysis for lactoferrin (LTF) using nested models. The left column shows results based on plasma data; the right column shows results based on CSF data. For LTF1, survival rates were compared between LTF1 high and LTF1 low. For LTF2, samples were split by the median (High: ≥ median; Low: < median). Model1: Surv(Time(years), status) ~ LTF + Age_LP + sex + education + mmse_csf; Model2: Surv(Time(years), status) ~ LTF + csf_ p_tau + PRS + APOE + Age_LP + sex + education + mmse_csf. HR represents the hazard ratio of the positive group, 95% confidence intervals is included, and p is the corresponding p-value.



Fig. S1. Scatter plots showing the correlations between LTF1/LTF2 and AD biomarkers (Aβ, p-tau, and t-tau).

The top row shows correlations with LTF1, and the bottom row with LTF2. LTF1 is stratified by LTF1 expression—LTF1-high (yellow) vs LTF1-low (blue). For LTF2, correlations were computed across all samples. Spearman correlation coefficients (r) and corresponding *p* values (*p*) are indicated in each panel.


AD Status
Amyloid β
Tau
(N)
APOE
Syndromic Status
mci dementia conversion
A+T+ v.s. A-T-
A+T+ v.s. A-T-(N)+
LTF1 CSF
LTF1 Plasma
LTF2 CSF
LTF2 Plasma
LTF1 CSF (N)
LTF1 Plasma (N)
LTF2 CSF (N)
LTF2 Plasma (N)
Log2(LTF + 1)
Low
High
Control
MCI
Dementia

Fig. S2. Comparison of LTF1 and LTF2 levels across AD biomarker profiles, clinical diagnosis, APOE genotypes, and longitudinal conversion status. Each row represents a comparison between groups stratified by APOE genotype, dementia diagnosis, A/T/N biomarker positivity, or longitudinal conversion status. Columns 1 – 2 show CSF and plasma LTF1 levels stratified by LTF1 abundance (high, low) respectively; columns 3 – 4 show the CSF and plasma LTF1 levels before stratification. Columns 5 – 6 show CSF and plasma LTF2 levels. In each plot, different color were used to discriminate the status of diagnosis, AD biomarkers, APOE genotypes or conversion status respectively. Statistical comparisons were performed using the Kruskal-Wallis test.

	AptName	SeqId	Target	UniProt	EntrezGene	Dilution	Plasma (Mean)	CSF (Mean)	Plasma (SD)	CSF (SD)	Plasma (Range)	CSF (Range)
LTF1	Seq.14755.4	14755-4	Lactoferrin	P02788	4,057	20%	370	132	469	79	[193.4, 14246.5]	[98.2, 2525.2]
LTF2	Seq.2780.35	2780-35	Lactoferrin	P02788	4,057	0.005%	1,260	19,951	4,703	20,804	[288.4,169268.3]	[326.3, 161054.1]

Table S1. Annotation of the two SOMAmers that target to LTF.

	Control (113)	MCI (833)	Dementia (394)	NA (29)	Total (1,369)
Age_LP	66.593 (7.039)	72.487 (7.992)	74.851 (7.497)	50.263 (13.32)	72.21 (8.807)
csf_abeta_42	1068.717 (377.948)	844.449 (415.512)	689.87(319.293)	1045.034 (384.142)	822.819 (400.566)
csf_p_tau	45.292 (19.054)	69.192 (40.396)	85.45 (54.522)	35.69 (16.557)	71.178 (44.99)
csf_tau	277.912 (120.454)	439.148 (276.461)	574.293 (402.932)	250.759 (117.47)	460.66 (319.743)
mmse_csf	29.396 (1.04)	25.759 (3.191)	20.614 (4.567)	NaN (NA)	24.525 (4.465)
qalb	0.006 (0.002)	0.006 (0.002)	0.007 (0.005)	0.005 (0.001)	0.006 (0.003)
apoe_e2e2	0	2	1	1	4
apoe_e2e3	21	49	24	0	94
apoe_e2e4	3	14	7	0	24
apoe_e3e3	64	480	213	22	779
apoe_e3e4	20	227	123	6	376
apoe_e4e4	3	41	20	0	64
atn_A-T-N-	79	251	69	19	418
atn_A-T-N+	0	11	3	2	16
atn_A-T+N-	3	33	6	0	42
atn_A-T+N+	7	115	45	1	168
atn_A+T-N-	13	119	64	6	202
atn_A+T-N+	0	5	5	0	10
atn_A+T+N-	2	59	10	0	71
atn_A+T+N+	9	240	191	1	441
mci_dementia_conversion_1y_0n_0	0	386	0	0	386
mci_dementia_conversion_1y_0n_1	0	367	0	0	367
Gender_Male	46	378	140	13	577
Gender_Female	67	455	254	16	792

Table S2. Demographic and clinical data of the participants in the ACE cohort.

Abbreviations: LP: lumbar puncture; MCI, mild cognitive impairment; AD, Alzheimer's disease dementia; MMSE, Mini Mental State Examination; LTF, Lactoferrin; NA, not applicable; sd, standard deviation.